Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.

ABSTRACT:

Background

To date, only a few studies reported data regarding the development of mucosal immune response after the BNT162b2-booster vaccination.

Methods

Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose (T3) and after two weeks (T4). Anti-S1-protein IgG and IgA antibody titres and the neutralizing antibodies against the Wuhan wild-type Receptor-Binding Domain in both serum and saliva were measured by quantitative and competitive ELISA, respectively. Data were compared with those recorded after the primary vaccination cycle (T2). Neutralizing antibodies against the variants of concern were measured in those individuals with anti-Wuhan neutralizing antibodies in their saliva.

Findings

After eight months from the sec

SUBMITTER: Azzi L 

PROVIDER: S-EPMC9828819 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature